Ophthalmology drug market size of more than 100 billion "lack of medicine and medicine" is still to be solved

January 6, Japan's Ssingtian Pharmaceutical Company announced that it has selected industrial land in Suzhou Industrial Park for the construction of the second pharmaceutical plant of Suzhou Pharmaceuticals (China) Co., Ltd.Pharmaceuticals' Teflon Prostatin (eye drops, the commodity name "Teplus") was selected in the 2019 health care negotiations for health care payment products, the price reduction reached 72.3 percent, the price of health insurance payments of 74.8 yuan. It is reported that this product is the main drug used in the treatment of glare in the pharmaceutical eye, in November 2015 was approved for listing in China."Despite the growing ageing population, China's economy will continue to grow at a high rate, and the ophthalmology market will expand further as the number of patients continues to increase and the health care system continues to improve,"Suntian Pharmaceutical Co., Ltd. President and Chief Operating Officer, Mr. Gu, told reporters. We have decided to build a new product supply plant to further support our business development in China. The Chinese business has now become and has long been the growth engine and largest overseas business. The company will further enhance its competitiveness by ensuring adequate supply and excellent quality of its products. " Eye medicine industry competition is fierce it is understood that due to the aging of the population, electronic products widely used, improper use of the eye and other lifestyle changes, so that the incidence of various types of eye diseases in China is on the rise, eye infections, conjunctivitis, macular degeneration, dry eye disease and other eye diseases increased significantly.2013-2017, China's ophthalmology market grew from 46.7 billion yuan to 86.6 billion yuan, with a compound annual growth rate of 16.7%, according to the data. With the increase of ophthalmology incidence, the upgrading of ophthalmology treatment technology and the improvement of patient's awareness of diagnosis and treatment, the size of ophthalmology market in China is expected to continue to grow at a rate of about 14% between 2018 and 2022. Shen Wanhongyuan Research Forecast, the total size of the ophthalmology market is expected to exceed 100 billion yuan.the rapid growth of the market size, but also bring enterprises to add code.reporter combed found that at present, including Japan, Novarce, the United States, such as foreign pharmaceutical giants and the rapid rise of domestic ophthalmology drug companies, Kanghong Pharmaceuticals, Sansheng Pharmaceuticals, Xingqi Eye Medicine, Zhuhai Yisheng, etc. are in the plus-code card position., Hengrui Pharmaceuticals spent heavily to introduce two innovative eye drugs in Germany to enter the ophthalmology market. It is reported that the two drugs are mainly used for dry eye disease, after the agreement is reached, Hengrui will be the two products in China's clinical development, production and marketing rights.because of the particularity of the eye structure, systemic drug delivery can not reach the eye lesions department in a timely and effective manner, only when the infection is more serious use of systemic medication. Therefore, the treatment of ophthalmological diseases, especially eye watch diseases, generally use local drug treatment methods, mainly eye drops, ointments, injections, gels, eye cavity application drugs.reporters in the interview learned that ophthalmology drugs are mainly divided into anti-eye bacterial infection drugs, anti-eye viral infection drugs, reduced eye pressure drugs, dispersal drugs, eye local narcotics and so on. In 2019, the National List of Essential Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drugs has 75 regulations for ophthalmology chemicals, the main dosage form is eye drops, for 52 regulations, accounting for 69.33 percent.According to the introduction, the new drug factory in Suzhou is mainly used for the production of eye drops products, Santseng Pharmaceuticals has now covered more than 10 kinds of ophthalmology prescription drugs and over-the-counter drugs including cataracts, retinal, glare, dry eyes, infections and allergies. Among them, the left oxyfluorosa star (commodity name: cola bito), sodium glass acid (commodity name: Aly), oxyfluorosa star (commodity name: Tali bito) for the company's main products.business has grown rapidly in recent years, accounting for 60 per cent of the region's total. Yamada Gui, general manager of Sant's China division, said the huge potential of the Chinese market provided an opportunity for the rapid growth of Ssant's China. He further revealed that anti-infective drugs and dry eye potions are the biggest growth engines for Sant'Sant's pharmaceutical industry.foreign investment, "lack of medical treatment and few medicines" is still to be solved China's ophthalmology drug market is a fast-growing area. However, due to the complex structure of the eye, part of the structure such as cornea and optic nerve is non-renewable, so the development of ophthalmology drugs need to be based on a complete and in-depth understanding of ophthalmology, the technical requirements are higher. This raises the threshold for the development of ophthalmology drugs further. In addition, the domestic ophthalmology enterprises started late, the foundation and technology accumulation want to be weak, but also make Tiantian Pharmaceuticals, Novarma Pharmaceuticals, Alcon and other foreign investment in the domestic market is still dominant.2018, imported drugs accounted for 64.08 percent of ophthalmology use in public hospitals in key provinces and cities, while domestic drugs accounted for only 35.92 percent, according to the data. Top5 in the ophthalmology market is Novarce in Switzerland at 25.35 percent, Japan at 14.24 percent, Ursapharm in Germany at 6.32 percent and Xingqi eye medicine in Shenyang at 4.71 percent.addition, the reporter also learned in the interview, ophthalmology field, "lack of medical treatment and medicine" phenomenon is still unresolted.head of a private ophthalmology hospital in Fujian told reporters that there is a shortage of therapeutic drugs in the field of ophthalmology in China. At present, most eye diseases are difficult to cure by drugs, which usually only slow the progression of the disease, such as glaucoma and diabetic macular edema (DME), so patients prefer surgery for thorough treatment., she says: "Ophthalmology devices play a more critical role than eye medicine. At present, most eye diseases are mainly surgical treatment, and due to the complexity of eye structure, surgery is more dependent on the device, the drug is usually used as an auxiliary treatment. " eye medicine seems to be a very small market segment, but the potential behind it is immeasurable, which is why domestic and foreign enterprises compete to add weight, increase efforts. Yamada Guigui told reporters that Santian Pharmaceuticals is still very happy to see more and more ophthalmology enterprises to participate in market competition, which is conducive to the benign development of the market and consumers meet different needs. he believes that the relative immaturity of certain areas of the ophthalmology market is challenging for companies. "The gla glare field is an important area in the world, and we have very good products," he said. In some countries, the glare market is generally the largest market, while in China, gla glare is only in the fourth and fifth position. This proves that many potential glare patients do not actually receive treatment or medication. In , in addition to glaucosis, market segments including cataracts, under-the-eye disease and corneal disease also show low therapeutic penetration. (First Finance)